A-3 Price List - Widaplik - Antihypertensive Agents-NA.xlsx
XLSX spreadsheet 45 KB Posted
- Solicitation number
- HT9402-26-Q-9302
- Issued by
-
Defense Health Agency
About this file
This is a pricing template for the Department of Defense (DoD) Uniform Formulary (UF) Blanket Purchase Agreement and Additional Discount Program for antihypertensive agents. The file is associated with solicitation HT9402-26-Q-9302 and is structured as a price list for ten newly approved pharmaceutical products in the antihypertensive agents class, with a P&T Committee meeting scheduled for August 5-6, 2026. Quotes are due by May 28, 2026. The Defense Health Agency is seeking pricing quotes organized across multiple appendices: a BPA UF section for both Military Treatment Facility and Mail Order scenarios with Uniform Formulary and Non-Formulary categories, an ADP section with non-FAMP discounts based on Federal Ceiling Price calculations, and an ADP section with WAC (Wholesale Acquisition Cost) discounts. For each of the ten drugs, manufacturers must submit price per unit for specified package sizes and indicate formulary tier placement (Tier 2 or Tier 3 for retail refund scenarios).
Key submission requirements include providing fully executed signature pages and a Quote Review Checklist alongside all quote information. Per the formulary notes, agents may be designated as preferred status by treating non-generic pharmaceuticals as generic products for cost-sharing purposes, or may face complete exclusion from the TRICARE pharmacy benefit program. Step therapy designations may apply, with agents not selected potentially designated as non-step preferred (after-step). The price per unit must be uniform across all available package sizes within a given dispensing venue. This template represents a critical component of the military health system's pharmaceutical acquisition process governed by 10 U.S.C. 1074g and 32 CFR Section 199.21.
View the file
Other files
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264AHNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 264AHNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | ANTIHYPERTENSIVE AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | May 28, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264AHNAG1T21M | Tier 2 | 1 or more | |
| 264AHNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .